Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 181

1.

BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories.

Capoluongo E, La Verde N, Barberis M, Bella MA, Buttitta F, Carrera P, Colombo N, Cortesi L, Gion M, Guarneri V, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A, Gori S.

Diagnostics (Basel). 2019 Oct 9;9(4). pii: E146. doi: 10.3390/diagnostics9040146.

2.

Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib.

Esposito Abate R, Pasquale R, Sacco A, Piccirillo MC, Morabito A, Bidoli P, Finocchiaro G, Chiari R, Foltran L, Buosi R, Tiseo M, Giannetta L, Battiloro C, Fasola G, Romano G, Ciuffreda L, Frassoldati A, de Marinis F, Cappuzzo F, Normanno N.

Cancers (Basel). 2019 Sep 25;11(10). pii: E1431. doi: 10.3390/cancers11101431.

3.

Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol.

Ottaiano A, Scala S, Normanno N, Napolitano M, Capozzi M, Rachiglio AM, Roma C, Trotta AM, D'Alterio C, Portella L, Romano C, Cassata A, Casaretti R, Silvestro L, Nappi A, Tafuto S, Avallone A, De Stefano A, Tamburini M, Picone C, Petrillo A, Izzo F, Palaia R, Albino V, Amore A, Belli A, Pace U, Di Marzo M, Chiodini P, Botti G, De Feo G, Delrio P, Nasti G.

BMC Cancer. 2019 Sep 9;19(1):899. doi: 10.1186/s12885-019-6109-z.

4.

Pembrolizumab in lung cancer: current evidence and future perspectives.

Palumbo G, Carillio G, Manzo A, Montanino A, Sforza V, Costanzo R, Sandomenico C, Manna C, Luca G, Piccirillo MC, Daniele G, Cecio R, Botti G, Totaro G, Muto P, Picone C, Esposito G, Normanno N, Morabito A.

Future Oncol. 2019 Oct;15(29):3327-3336. doi: 10.2217/fon-2019-0073. Epub 2019 Aug 21.

PMID:
31432705
5.

Conditioned medium of primary lung cancer cells induces EMT in A549 lung cancer cell line by TGF-ß1 and miRNA21 cooperation.

Camerlingo R, Miceli R, Marra L, Rea G, D'Agnano I, Nardella M, Montella R, Morabito A, Normanno N, Tirino V, Rocco G.

PLoS One. 2019 Jul 25;14(7):e0219597. doi: 10.1371/journal.pone.0219597. eCollection 2019.

6.

Application of the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) to patients conservatively treated: Outcomes from an institutional series.

Falcone F, Normanno N, Losito NS, Scognamiglio G, Esposito Abate R, Chicchinelli N, Casella G, Laurelli G, Scaffa C, Greggi S.

Eur J Obstet Gynecol Reprod Biol. 2019 Sep;240:220-225. doi: 10.1016/j.ejogrb.2019.07.013. Epub 2019 Jul 13.

PMID:
31326637
7.

Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer.

Elez E, Chianese C, Sanz-García E, Martinelli E, Noguerido A, Mancuso FM, Caratù G, Matito J, Grasselli J, Cardone C, Esposito Abate R, Martini G, Santos C, Macarulla T, Argilés G, Capdevila J, Garcia A, Mulet N, Maiello E, Normanno N, Jones F, Tabernero J, Ciardello F, Salazar R, Vivancos A.

Mol Oncol. 2019 Sep;13(9):1827-1835. doi: 10.1002/1878-0261.12547. Epub 2019 Jul 31.

8.

The potential of monitoring treatment response in non-small cell lung cancer using circulating tumour cells.

Gallo M, De Luca A, Frezzetti D, Passaro V, Maiello MR, Normanno N.

Expert Rev Mol Diagn. 2019 Aug;19(8):683-694. doi: 10.1080/14737159.2019.1640606. Epub 2019 Jul 15.

PMID:
31305173
9.

Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion.

Berghoff AS, Bellosillo B, Caux C, de Langen A, Mazieres J, Normanno N, Preusser M, Provencio M, Rojo F, Wolf J, Zielinski CC.

ESMO Open. 2019 Jun 17;4(3):e000498. doi: 10.1136/esmoopen-2019-000498. eCollection 2019. Review.

10.

Extracellular matrix proteins as circulating biomarkers for the diagnosis of non-small cell lung cancer patients.

Frezzetti D, De Luca A, Normanno N.

J Thorac Dis. 2019 May;11(Suppl 9):S1252-S1256. doi: 10.21037/jtd.2019.02.46. No abstract available.

11.

Genomic Profiling of KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents.

Rachiglio AM, Lambiase M, Fenizia F, Roma C, Cardone C, Iannaccone A, De Luca A, Carotenuto M, Frezzetti D, Martinelli E, Maiello E, Ciardiello F, Normanno N.

Cancers (Basel). 2019 Jun 20;11(6). pii: E859. doi: 10.3390/cancers11060859.

12.

Circulating free tumor-derived DNA to detect EGFR mutations in patients with advanced NSCLC: French subset analysis of the ASSESS study.

Denis MG, Lafourcade MP, Le Garff G, Dayen C, Falchero L, Thomas P, Locher C, Oliviero G, Licour M, Reck M, Normanno N, Molinier O.

J Thorac Dis. 2019 Apr;11(4):1370-1378. doi: 10.21037/jtd.2019.03.95.

13.

Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.

Gori S, Barberis M, Bella MA, Buttitta F, Capoluongo E, Carrera P, Colombo N, Cortesi L, Genuardi M, Gion M, Guarneri V, Incorvaia L, La Verde N, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A; AIOM-SIGU-SIBIOC-SIAPEC-IAP Working Group.

Crit Rev Oncol Hematol. 2019 Aug;140:67-72. doi: 10.1016/j.critrevonc.2019.05.012. Epub 2019 May 25.

14.

Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial.

Perrone F, De Laurentiis M, De Placido S, Orditura M, Cinieri S, Riccardi F, Ribecco AS, Putzu C, Del Mastro L, Rossi E, Tinessa V, Mosconi AM, Nuzzo F, Di Rella F, Gravina A, Iodice G, Landi G, Pacilio C, Forestieri V, Lauria R, Fabbri A, Ibrahim T, De Maio E, Barni S, Gori S, Simeon V, Arenare L, Daniele G, Piccirillo MC, Normanno N, de Matteis A, Gallo C.

Eur J Cancer. 2019 Sep;118:178-186. doi: 10.1016/j.ejca.2019.05.004. Epub 2019 Jun 1.

PMID:
31164265
15.

IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing.

Deans ZC, Butler R, Cheetham M, Dequeker EMC, Fairley JA, Fenizia F, Hall JA, Keppens C, Normanno N, Schuuring E, Patton SJ.

Virchows Arch. 2019 Jun;474(6):681-689. doi: 10.1007/s00428-019-02571-3. Epub 2019 Apr 26.

16.

The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer.

Pignata S, Scambia G, Lorusso D, De Giorgi U, Nicoletto MO, Lauria R, Mosconi AM, Sacco C, Omarini C, Tagliaferri P, Ferrandina G, Cinieri S, Savarese A, Valabrega G, Pisano C, Salutari V, Raspagliesi F, Kopf B, Cecere SC, Amadio G, Maltese G, Di Napoli M, Greggi S, Signoriello S, Daniele G, Sacco A, Losito S, Normanno N, Perrone F, Gallo C, Piccirillo MC; MITO Investigators.

Gynecol Oncol. 2019 Jun;153(3):535-540. doi: 10.1016/j.ygyno.2019.03.260. Epub 2019 Apr 9.

PMID:
30979589
17.

The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients.

Rachiglio AM, Fenizia F, Piccirillo MC, Galetta D, Crinò L, Vincenzi B, Barletta E, Pinto C, Ferraù F, Lambiase M, Montanino A, Roma C, Ludovini V, Montagna ES, De Luca A, Rocco G, Botti G, Perrone F, Morabito A, Normanno N.

Cancers (Basel). 2019 Mar 10;11(3). pii: E341. doi: 10.3390/cancers11030341.

18.

EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.

Martini G, Cardone C, Vitiello PP, Belli V, Napolitano S, Troiani T, Ciardiello D, Della Corte CM, Morgillo F, Matrone N, Sforza V, Papaccio G, Desiderio V, Paul MC, Moreno-Viedma V, Normanno N, Rachiglio AM, Tirino V, Maiello E, Latiano TP, Rizzi D, Signoriello G, Sibilia M, Ciardiello F, Martinelli E.

Mol Cancer Ther. 2019 Apr;18(4):845-855. doi: 10.1158/1535-7163.MCT-18-0539. Epub 2019 Mar 1.

PMID:
30824612
19.

Implementing TMB measurement in clinical practice: considerations on assay requirements.

Büttner R, Longshore JW, López-Ríos F, Merkelbach-Bruse S, Normanno N, Rouleau E, Penault-Llorca F.

ESMO Open. 2019 Jan 24;4(1):e000442. doi: 10.1136/esmoopen-2018-000442. eCollection 2019.

20.

Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives.

Herbreteau G, Vallée A, Charpentier S, Normanno N, Hofman P, Denis MG.

J Thorac Dis. 2019 Jan;11(Suppl 1):S113-S126. doi: 10.21037/jtd.2018.12.18. Review.

Supplemental Content

Loading ...
Support Center